165 related articles for article (PubMed ID: 17931049)
1. Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function.
Borchert M; Schöndorf T; Lübben G; Forst T; Pfützner A
Diabetes Technol Ther; 2007 Oct; 9(5):410-20. PubMed ID: 17931049
[TBL] [Abstract][Full Text] [Related]
2. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
3. Pleiotropic effects of PPARγ agonist on hemostatic activation in type 2 diabetes mellitus.
Ferroni P; Della-Morte D; Pileggi A; Riondino S; Rundek T; Ricordi C; Guadagni F
Curr Vasc Pharmacol; 2013 May; 11(3):338-51. PubMed ID: 23650948
[TBL] [Abstract][Full Text] [Related]
4. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
5. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
Orasanu G; Ziouzenkova O; Devchand PR; Nehra V; Hamdy O; Horton ES; Plutzky J
J Am Coll Cardiol; 2008 Sep; 52(10):869-81. PubMed ID: 18755353
[TBL] [Abstract][Full Text] [Related]
6. Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone.
Randriamboavonjy V; Pistrosch F; Bölck B; Schwinger RH; Dixit M; Badenhoop K; Cohen RA; Busse R; Fleming I
Circulation; 2008 Jan; 117(1):52-60. PubMed ID: 18071073
[TBL] [Abstract][Full Text] [Related]
7. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
Defronzo RA; Mehta RJ; Schnure JJ
Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Significance of PPAR Gamma Agonism.
Campbell IW
Curr Mol Med; 2005 May; 5(3):349-63. PubMed ID: 15892654
[TBL] [Abstract][Full Text] [Related]
9. Thiazolidinediones and PPARγ agonists: time for a reassessment.
Cariou B; Charbonnel B; Staels B
Trends Endocrinol Metab; 2012 May; 23(5):205-15. PubMed ID: 22513163
[TBL] [Abstract][Full Text] [Related]
10. Recent findings concerning thiazolidinediones in the treatment of diabetes.
Boden G; Zhang M
Expert Opin Investig Drugs; 2006 Mar; 15(3):243-50. PubMed ID: 16503761
[TBL] [Abstract][Full Text] [Related]
11. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
Fogo AB
Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
[TBL] [Abstract][Full Text] [Related]
12. 3T3-L1 adipocyte apoptosis induced by thiazolidinediones is peroxisome proliferator-activated receptor-gamma-dependent and mediated by the caspase-3-dependent apoptotic pathway.
Xiao Y; Yuan T; Yao W; Liao K
FEBS J; 2010 Feb; 277(3):687-96. PubMed ID: 20050918
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives.
Chiarelli F; Di Marzio D
Vasc Health Risk Manag; 2008; 4(2):297-304. PubMed ID: 18561505
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
Ríos-Vázquez R; Marzoa-Rivas R; Gil-Ortega I; Kaski JC
Am J Cardiovasc Drugs; 2006; 6(4):231-42. PubMed ID: 16913824
[TBL] [Abstract][Full Text] [Related]
15. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
Duan SZ; Usher MG; Mortensen RM
Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
[TBL] [Abstract][Full Text] [Related]
18. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats.
Park SW; Yi JH; Miranpuri G; Satriotomo I; Bowen K; Resnick DK; Vemuganti R
J Pharmacol Exp Ther; 2007 Mar; 320(3):1002-12. PubMed ID: 17167171
[TBL] [Abstract][Full Text] [Related]
19. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
Panunti B; Fonseca V
Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
[TBL] [Abstract][Full Text] [Related]
20. [Recent trends in PPARgamma agonist development of thiazolidinediones and non-thiazolidinediones].
Tanaka T
Nihon Rinsho; 2010 Feb; 68(2):249-55. PubMed ID: 20158092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
